Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical and pathological characteristics of the cohort

From: Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

  Mean ± SD N
Age (years) 63.5 ± 6.5 98
Prostatic volume (c.c) 44.4 ± 22.4 98
Testosterone (nmol/L) 13.9 ± 4.9 98
Total PSA (ng/mL) 9.7 ± 8.20 98
   N (%)
BMI (kg/m2) < 25 21 (21.7)
25–29.99 50 (51.6)
≥ 30 26 (26.7)
Total PSA (µg/L) < 4 7 (7.2)
4–10 60 (61.9)
> 10 30 (30,9)
ISUP GG
 Low risk Group I 38 (38,8)
Group II 24 (24,5)
 High risk Group III 19 (19.3)
Group IV 10 (10.2)
Group V 7 (7.2)
T pathological stage ≤ T2a 69 (70.4)
T3, T4 29 (29,6)
No pathological stage NX 53 (55.8)
N0 36 (37.9)
N1 6 (6.3)
  1. N number of patients, SD standard deviation, BMI body mass index, ISUP GG ISUP Grade Groups based on the Gleason score as follows: (Gleason score ≤ 6 group I; 3 + 4=7 group II; 4 + 3=7 group III; 4 + 4=8 group IV; and 9–10 group V); T-stage tumor category; N lymph node category